Literature DB >> 11916550

Paediatric embryonic brain tumours. biological and clinical relevance of molecular genetic abnormalities.

R Gilbertson1.   

Abstract

Embryonal tumours constitute the largest group of malignant paediatric brain tumours. Their origin and histological classification remain somewhat controversial. However, in recent years real progress has been made in our understanding of the molecular genetic abnormalities that govern the initiation and/or progression of these tumours. A number of these abnormalities appear to involve alterations in signalling systems that control normal cerebellar development. Increasing our understanding of both the biology and clinical relevance of these molecular defects is a major challenge to the field of paediatric neuro-oncology. However, it likely represents the only means by which we will advance the management of these tumours, significantly reducing disease-related morbidity and mortality. This review focuses on the principal molecular genetic abnormalities so far identified in embryonal brain tumours and discusses their biological and clinical relevance.

Entities:  

Mesh:

Year:  2002        PMID: 11916550     DOI: 10.1016/s0959-8049(01)00315-x

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  11 in total

1.  Medulloblastoma in mice lacking p53 and PARP: all roads lead to Gli.

Authors:  Charles G Eberhart
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

2.  RASSF1A and the BH3-only mimetic ABT-737 promote apoptosis in pediatric medulloblastoma cell lines.

Authors:  Jane Levesley; Meryl E Lusher; Janet C Lindsey; Steven C Clifford; Richard Grundy; Beth Coyle
Journal:  Neuro Oncol       Date:  2011-08-31       Impact factor: 12.300

3.  Medulloblastoma.

Authors:  Catherine A. Mazzola; Ian F. Pollack
Journal:  Curr Treat Options Neurol       Date:  2003-05       Impact factor: 3.598

Review 4.  Recent advances in embryonal tumours of the central nervous system.

Authors:  Chitra Sarkar; Prabal Deb; Mehar Chand Sharma
Journal:  Childs Nerv Syst       Date:  2005-01-29       Impact factor: 1.475

5.  LIN28A, a sensitive immunohistochemical marker for Embryonal Tumor with Multilayered Rosettes (ETMR), is also positive in a subset of Atypical Teratoid/Rhabdoid Tumor (AT/RT).

Authors:  Shilpa Rao; R T Rajeswarie; T Chickabasaviah Yasha; Bevinahalli N Nandeesh; Arimappamagan Arivazhagan; Vani Santosh
Journal:  Childs Nerv Syst       Date:  2017-07-25       Impact factor: 1.475

6.  Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth.

Authors:  Yvette M Carter; Selvi Kunnimalaiyaan; Herbert Chen; T Clark Gamblin; Muthusamy Kunnimalaiyaan
Journal:  Cancer Biol Ther       Date:  2014-02-12       Impact factor: 4.742

Review 7.  Physiological and pathological roles of Apaf1 and the apoptosome.

Authors:  E Ferraro; M Corvaro; F Cecconi
Journal:  J Cell Mol Med       Date:  2003 Jan-Mar       Impact factor: 5.310

8.  Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma.

Authors:  Anna Wojtalla; Fabiana Salm; Ditte G Christiansen; Tiziana Cremona; Paulina Cwiek; Tarek Shalaby; Nicole Gross; Michael A Grotzer; Alexandre Arcaro
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

9.  Current therapy for medulloblastoma.

Authors:  Nicholas G Gottardo; Amar Gajjar
Journal:  Curr Treat Options Neurol       Date:  2006-07       Impact factor: 3.972

10.  The Phosphoinositide 3-Kinase p110α Isoform Regulates Leukemia Inhibitory Factor Receptor Expression via c-Myc and miR-125b to Promote Cell Proliferation in Medulloblastoma.

Authors:  Fabiana Salm; Valeriya Dimitrova; André O von Bueren; Paulina Ćwiek; Hubert Rehrauer; Valentin Djonov; Pascale Anderle; Alexandre Arcaro
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.